Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Operating Margin (2016 - 2025)

United Therapeutics' Operating Margin history spans 17 years, with the latest figure at 45.14% for Q4 2025.

  • For Q4 2025, Operating Margin rose 457299.0% year-over-year to 45.14%; the TTM value through Dec 2025 reached 46.89%, down 1764.0%, while the annual FY2025 figure was 46.89%, 96.0% down from the prior year.
  • Operating Margin for Q4 2025 was 45.14% at United Therapeutics, down from 48.59% in the prior quarter.
  • Across five years, Operating Margin topped out at 26010.0% in Q4 2023 and bottomed at 4527.85% in Q4 2024.
  • The 5-year median for Operating Margin is 48.39% (2025), against an average of 1115.12%.
  • The largest annual shift saw Operating Margin surged 2597427bps in 2023 before it crashed -3053785bps in 2024.
  • A 5-year view of Operating Margin shows it stood at 40.9% in 2021, then decreased by -13bps to 35.73% in 2022, then soared by 72701bps to 26010.0% in 2023, then crashed by -117bps to 4527.85% in 2024, then surged by 101bps to 45.14% in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Operating Margin are 45.14% (Q4 2025), 48.59% (Q3 2025), and 45.64% (Q2 2025).